![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NCMAP |
Gene summary for NCMAP |
![]() |
Gene information | Species | Human | Gene symbol | NCMAP | Gene ID | 400746 |
Gene name | non-compact myelin associated protein | |
Gene Alias | C1orf130 | |
Cytomap | 1p36.11 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q5T1S8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
400746 | NCMAP | HCC1_Meng | Human | Liver | HCC | 1.60e-12 | -1.56e-02 | 0.0246 |
400746 | NCMAP | HCC1 | Human | Liver | HCC | 4.30e-19 | 2.07e+00 | 0.5336 |
400746 | NCMAP | HCC2 | Human | Liver | HCC | 5.26e-35 | 2.80e+00 | 0.5341 |
400746 | NCMAP | HCC5 | Human | Liver | HCC | 1.65e-26 | 1.82e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Thyroid | PTC | ![]() |
Thyroid | goiters | ![]() |
Thyroid | ATC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00072721 | Liver | HCC | ensheathment of neurons | 72/7958 | 136/18723 | 8.87e-03 | 3.44e-02 | 72 |
GO:00083661 | Liver | HCC | axon ensheathment | 72/7958 | 136/18723 | 8.87e-03 | 3.44e-02 | 72 |
GO:00425521 | Liver | HCC | myelination | 71/7958 | 134/18723 | 9.08e-03 | 3.49e-02 | 71 |
GO:00420631 | Liver | HCC | gliogenesis | 148/7958 | 301/18723 | 1.10e-02 | 4.07e-02 | 148 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NCMAP | SNV | Missense_Mutation | c.38T>G | p.Phe13Cys | p.F13C | Q5T1S8 | protein_coding | tolerated_low_confidence(0.06) | possibly_damaging(0.789) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
NCMAP | SNV | Missense_Mutation | novel | c.289N>T | p.Val97Phe | p.V97F | Q5T1S8 | protein_coding | deleterious(0) | benign(0.276) | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NCMAP | insertion | Frame_Shift_Ins | novel | c.290_291insCCCCGCGGCATACCAGGGGAAAGACTCAA | p.Gln98ProfsTer57 | p.Q98Pfs*57 | Q5T1S8 | protein_coding | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
NCMAP | SNV | Missense_Mutation | c.148N>A | p.Leu50Met | p.L50M | Q5T1S8 | protein_coding | tolerated(0.08) | probably_damaging(0.998) | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD | |
NCMAP | SNV | Missense_Mutation | c.179N>T | p.Thr60Met | p.T60M | Q5T1S8 | protein_coding | tolerated(0.2) | benign(0.015) | TCGA-B5-A11N-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
NCMAP | SNV | Missense_Mutation | novel | c.67G>T | p.Asp23Tyr | p.D23Y | Q5T1S8 | protein_coding | deleterious(0) | probably_damaging(0.919) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
NCMAP | SNV | Missense_Mutation | novel | c.58A>G | p.Arg20Gly | p.R20G | Q5T1S8 | protein_coding | deleterious(0.01) | benign(0) | TCGA-33-AASI-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | PD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |